Ultra-low Concentrations of Cisplatinum Down to the IC in Combination With Recombinant Methioninase Are Synergistically Effective Against Lung Cancer Cells and .
[BACKGROUND/AIM] To determine whether methionine restriction using recombinant methioninase (rMETase) enhances the efficacy of ultra-low-dose cisplatinum against lung cancer cells , and whether combin
APA
Asano Y, Han Q, et al. (2026). Ultra-low Concentrations of Cisplatinum Down to the IC in Combination With Recombinant Methioninase Are Synergistically Effective Against Lung Cancer Cells and .. In vivo (Athens, Greece), 40(2), 803-812. https://doi.org/10.21873/invivo.14238
MLA
Asano Y, et al.. "Ultra-low Concentrations of Cisplatinum Down to the IC in Combination With Recombinant Methioninase Are Synergistically Effective Against Lung Cancer Cells and .." In vivo (Athens, Greece), vol. 40, no. 2, 2026, pp. 803-812.
PMID
41760327
Abstract
[BACKGROUND/AIM] To determine whether methionine restriction using recombinant methioninase (rMETase) enhances the efficacy of ultra-low-dose cisplatinum against lung cancer cells , and whether combining a methionine-restricted (MR) diet with low-dose cisplatinum can inhibit lung cancer growth with reduced toxicity.
[MATERIALS AND METHODS] Human A549 lung adenocarcinoma cells were treated with rMETase and cisplatinum . Cell viability was assessed after 72 hours using the WST-8 reagent. The IC value of rMETase was determined, and synergy was evaluated by combining rMETase at its IC with cisplatinum at its determined IC-IC. For analysis, A549 xenografts were established in nude mice and assigned to four groups: control: standard-dose cisplatinum [6 mg/kg, intraperitoneally (), weekly]; low-dose cisplatinum (3 mg/kg, , weekly) + a methionine-restricted (MR) diet; or the MR diet alone. Treatments were administered for two weeks, with tumor size and body weight were monitored.
[RESULTS] For A549 lung-cancer cells the IC value of rMETase was 0.64 U/ml. Combination treatment with rMETase (IC) and cisplatinum (IC-IC) synergistically reduced cell viability compared with either agent alone, even at the IC of cisplatinum. , A549 tumor eradication was observed only in the low-dose cisplatinum + MR diet group. Standard-dose cisplatinum alone and MR-alone showed delayed or limited efficacy. Body-weight loss was minimal in the low-dose cisplatinum + MR group compared with the standard-dose cisplatinum group, indicating reduced systemic toxicity.
[CONCLUSION] Methionine restriction enhances the efficacy of ultra-low-dose cisplatinum on lung cancer cells . Low-dose cisplatinum in combination with an MR diet prevented lung-cancer growth in nude mice. The present approach of cancer therapy may help reduce platinum-related toxicity and improve treatment outcomes, suggesting further investigation for clinical translation.
[MATERIALS AND METHODS] Human A549 lung adenocarcinoma cells were treated with rMETase and cisplatinum . Cell viability was assessed after 72 hours using the WST-8 reagent. The IC value of rMETase was determined, and synergy was evaluated by combining rMETase at its IC with cisplatinum at its determined IC-IC. For analysis, A549 xenografts were established in nude mice and assigned to four groups: control: standard-dose cisplatinum [6 mg/kg, intraperitoneally (), weekly]; low-dose cisplatinum (3 mg/kg, , weekly) + a methionine-restricted (MR) diet; or the MR diet alone. Treatments were administered for two weeks, with tumor size and body weight were monitored.
[RESULTS] For A549 lung-cancer cells the IC value of rMETase was 0.64 U/ml. Combination treatment with rMETase (IC) and cisplatinum (IC-IC) synergistically reduced cell viability compared with either agent alone, even at the IC of cisplatinum. , A549 tumor eradication was observed only in the low-dose cisplatinum + MR diet group. Standard-dose cisplatinum alone and MR-alone showed delayed or limited efficacy. Body-weight loss was minimal in the low-dose cisplatinum + MR group compared with the standard-dose cisplatinum group, indicating reduced systemic toxicity.
[CONCLUSION] Methionine restriction enhances the efficacy of ultra-low-dose cisplatinum on lung cancer cells . Low-dose cisplatinum in combination with an MR diet prevented lung-cancer growth in nude mice. The present approach of cancer therapy may help reduce platinum-related toxicity and improve treatment outcomes, suggesting further investigation for clinical translation.
MeSH Terms
Humans; Carbon-Sulfur Lyases; Cisplatin; Animals; Mice; Lung Neoplasms; Xenograft Model Antitumor Assays; Drug Synergism; Recombinant Proteins; Methionine; Antineoplastic Agents; Cell Survival; A549 Cells; Cell Line, Tumor; Mice, Nude; Cell Proliferation
같은 제1저자의 인용 많은 논문 (4)
- Thoracoscopic biopsy should be considered for pulmonary nodules with the halo sign during immunotherapy for hepatocellular carcinoma.
- Selective Synergy of the Combination of Recombinant Methioninase With Cisplatinum and Ivermectin Which Eradicates Lung-Cancer Cells but Has No Synergy and Limited Effect on Normal Fibroblasts.
- Rapid Eradication of Extensive Spinal Metastases in a Prostate-Cancer Patient Taking Androgen-deprivation Therapy, Chemotherapy, and Oral Recombinant Methioninase on a Low-Methionine Diet.
- Triple Combination of Recombinant Methioninase and the Anti-parasitic Drugs Ivermectin, and Chloroquine Selectively Eradicates Pancreatic Cancer Cells While Sparing Normal Fibroblasts.